current
licens
vaccin
divid
three
broad
categori
genet
attenu
live
pathogen
remain
replicationcompet
greatli
diminish
abil
caus
diseas
kill
pathogen
chemic
inactiv
isol
subunit
fragment
pathogen
first
two
categori
repres
respect
classic
oral
sabin
inject
salk
polioviru
vaccin
initi
develop
quickli
appreci
liveattenu
immunogen
confer
durabl
immun
wildtyp
polioviru
replic
vaccin
individu
e
steril
immun
contrast
inactiv
immunogen
gener
provid
transient
protect
primarili
serv
prevent
spread
polioviru
central
nervou
system
oppos
fulli
prevent
viral
replic
gut
pattern
recapitul
respons
elicit
vaccin
exampl
liveattenu
immunogen
measl
smallpox
vaccin
provid
longterm
steril
immun
kill
pathogen
vaccin
induc
transient
respons
requir
period
boost
differ
least
partial
attribut
fact
live
immunogen
display
varieti
pathogenassoci
molecular
pattern
pamp
engag
innat
antimicrobi
sensor
tolllik
receptor
tlr
contrast
replicationincompet
immunogen
lack
innat
danger
signal
therefor
induc
diminish
delay
less
durabl
immun
respons
subunit
vaccin
respons
tend
follow
pattern
kill
pathogen
vaccin
familiar
exampl
tetanu
toxoid
vaccin
requir
period
boost
maintain
protect
level
tetanu
toxinneutr
antibodi
current
review
focu
new
class
immunogen
subunit
vaccin
immunogen
interest
organ
multival
array
resembl
surfac
geometr
rigid
virion
result
immunogen
term
viruslik
particl
vlp
typic
compos
recombin
virion
structur
protein
selfassembl
nanoparticl
absenc
viral
genom
dna
rna
well
establish
properli
assembl
vlp
induc
potent
divers
durabl
serum
antibodi
respons
compar
respons
live
liveattenu
pathogen
remark
potenc
rigidli
multival
subunit
immunogen
comprehens
document
studi
current
commerci
vlpbase
vaccin
human
papillomavirus
hpv
emerg
view
least
type
vlp
immunogen
includ
current
hpv
vaccin
fall
special
class
subunit
vaccin
show
potenc
durabl
liveattenu
immunogen
recent
clinic
trial
demonstr
vlp
immunogen
even
potent
enough
overcom
selftoler
human
b
cell
allow
induct
autoantibodi
respons
therapeut
interest
vlp
antigen
show
high
immunogen
hpv
vaccin
exampl
commerci
hepat
b
viru
hbv
vaccin
compris
vlp
assembl
hbv
surfac
envelop
protein
induc
rel
poor
antibodi
titer
declin
time
may
protein
array
rel
mobil
flexibl
way
thu
fail
qualifi
geometr
rigid
multival
structur
similar
flexibl
issu
might
explain
emerg
vlpbase
vaccin
dengu
viru
appear
elicit
stabl
hightit
neutral
antibodi
respons
clinic
trial
nearli
known
anim
virus
virion
diamet
nanomet
nm
rang
smaller
nm
virion
passiv
traffic
lymphat
system
also
directli
taken
immun
cell
macrophag
dendrit
cell
b
cell
either
pathway
effici
bring
antigen
lymph
node
adapt
immun
respons
induc
set
lymph
node
success
transport
virion
taken
special
macrophag
subcapsular
sinu
drain
lymph
node
virion
transfer
follicular
dendrit
cell
fdc
directli
present
b
cell
durabl
attach
fdc
enhanc
decor
present
antigen
low
affin
igm
antibodi
complement
compon
antigenspecif
surfac
immunoglobulin
ig
b
cell
b
cell
receptor
bcr
recogn
antigen
bcr
form
microclust
promot
signal
cascad
activ
b
cell
recogn
antigen
endocytos
process
present
mhc
class
ii
protein
turn
recruit
help
antigenspecif
cell
bachmann
zinkernagel
colleagu
show
b
cell
recogn
multival
antigen
repetit
angstrom
space
distinct
way
lead
potent
induct
cell
activ
surviv
signal
rigid
epitop
space
type
commonli
found
surfac
mani
type
virion
rare
among
vertebr
self
antigen
fact
host
protein
complex
space
immun
gene
product
igm
antibodi
complement
compon
collectin
like
mannos
bind
lectin
repetit
space
thu
seen
type
pamp
b
cell
evolv
specif
detect
via
engag
cell
surfac
bcr
strong
b
cell
respons
elicit
type
pamp
signal
engag
tolllik
receptor
tlr
persist
interact
fdc
igm
howev
bachmannzinkernagel
effect
oper
independ
convent
adjuv
signal
instead
epitop
space
rigid
appear
primari
variabl
trigger
effect
indirect
evid
multival
immunogen
trigger
special
type
signal
separ
adjuv
effect
come
observ
extrem
difficult
perhap
imposs
gener
hybridoma
mice
immun
rigid
viruslik
particl
dose
schedul
typic
use
product
monoclon
antibodi
use
mous
model
system
belhart
colleagu
recent
propos
model
solubl
monoval
antigen
trigger
signal
primarili
igmisotyp
bcr
multival
antigen
abl
trigger
signal
igdisotyp
bcr
found
fulli
matur
b
cell
hing
region
surfac
ig
isotyp
critic
determin
sensit
rigidli
multival
antigen
current
hypothesi
intern
multival
antigen
via
igd
may
lead
enhanc
present
antigen
cell
initi
unclear
whether
bachmannzinkernagel
effect
would
applic
human
extraordinari
success
current
rigid
multival
vlp
vaccin
hpv
confirm
relev
human
popul
particip
earli
trial
hpv
vaccin
receiv
one
dose
vaccin
demonstr
high
titer
neutral
antibodi
respons
plateau
least
six
year
vaccin
fig
booster
dose
hpv
vaccin
caus
increment
increas
antibodi
titer
type
respons
stand
dramat
contrast
convent
immunogen
tradit
tetanu
toxoid
vaccin
booster
dose
trigger
major
albeit
temporari
rise
neutral
antibodi
titer
fig
possibl
interpret
given
b
cell
initi
contact
vlp
immunogen
trigger
differenti
pathwaypresum
mediat
igd
bcrsthat
predispos
cell
expand
differenti
set
longliv
plasma
cell
resid
bone
marrow
without
necessarili
pass
durabl
memori
b
cell
phenotyp
success
current
hpv
vaccin
demonstr
recombin
particl
assembl
natur
rigid
icosahedr
virion
protein
provid
durabl
antibodybas
steril
immun
pathogen
virus
surpris
featur
hpv
vaccin
induc
antibodi
respons
capabl
crossprotect
women
infect
hpv
serotyp
nt
present
vaccin
prepar
newer
version
hpv
vaccin
contain
vlp
repres
nine
differ
hpv
serotyp
presenc
multipl
antigen
singl
vaccin
littl
impact
induct
respons
nine
type
outcom
hpv
vlp
vaccin
suggest
promis
path
develop
vlp
vaccin
divers
famili
virus
natur
rigid
icosahedr
virion
knobbi
nonenvelop
icosahedr
surfac
polyomaviru
virion
one
exampl
polyomavirus
similar
papillomaviru
virion
two
viral
famili
origin
classifi
singl
viral
famili
papovavirida
base
appear
electron
micrograph
vlp
base
two
pathogen
human
polyomavirus
known
bkv
jcv
current
investig
possibl
vaccin
immunogen
compassion
use
case
studi
elderli
immunodefici
patient
given
experiment
jcv
vlp
vaccin
demonstr
remark
high
jcvneutral
serolog
titer
approxim
million
result
consist
idea
polyomaviru
vlp
immunogen
may
least
potent
current
hpv
vlp
vaccin
number
import
human
pathogen
natur
rigid
icosahedr
surfac
one
exampl
chikungunya
viru
member
alphaviru
famili
vlp
assembl
icosahedr
rigid
envelop
glycoprotein
chikungunya
viru
elicit
hightit
neutral
antibodi
respons
anim
model
human
trial
norovirus
repres
anoth
promis
target
vlp
vaccin
develop
result
clinic
trial
vlpbase
vaccin
noroviru
current
consider
us
food
drug
administr
recent
success
vlpbase
vaccin
canin
parvoviru
suggest
compar
vlpbase
vaccin
human
parvoviru
feasibl
human
rhinovirus
natur
icosahedr
nonenvelop
virus
thu
may
repres
anoth
facil
target
vlp
vaccin
develop
rhinovirus
collect
caus
mild
upper
respiratori
infect
human
although
least
known
rhinoviru
serotyp
may
eventu
possibl
construct
panel
recombin
rhinoviru
vlp
inclus
multivlp
vaccin
analog
nineserotyp
hpv
vlp
vaccin
base
assumpt
multivlp
rhinoviru
vaccin
immunogen
would
like
hpv
vlp
vaccin
elicit
least
degre
crossneutr
rhinoviru
serotyp
contain
vaccin
approach
could
theoret
offer
broad
protect
common
cold
project
could
serv
pave
way
develop
vlpbase
vaccin
virus
picornavirida
famili
includ
emerg
pathogen
associ
flaccid
paralysi
mention
vlp
base
flavivirus
dengu
viru
far
elicit
poor
immunogen
despit
potenti
icosahedr
display
surfac
premembran
prm
envelop
e
protein
structur
studi
dengu
virion
vlp
indic
e
exist
rang
highli
distinct
conform
major
conform
shift
trigger
proteolysi
prm
cellular
proteas
furin
structureguid
design
engin
complet
proteolysi
recombin
dengu
vlp
might
result
rigid
display
uniformli
matur
herringbon
configur
e
protein
therebi
effect
trigger
backmannzinkernagel
effect
initi
work
reveal
bachmannzinkernagel
effect
reli
use
vesicular
stomat
viru
vsv
model
system
like
member
viral
famili
rhabdovirida
surfac
envelop
glycoprotein
g
vsv
icosahedr
order
vsv
g
howev
array
high
densiti
bulletshap
surfac
virion
suggest
strict
geometr
rigid
necessarili
requir
trigger
bachmannzinkernagel
effect
form
extrem
highdens
polyval
suffic
advanc
structur
biolog
nanotechnolog
open
new
opportun
design
synthet
vaccin
immunogen
basi
atomiclevel
inform
design
mimic
number
biolog
macromolecul
includ
cargo
protein
multimer
enzym
subvir
particl
viral
capsid
selfassembl
protein
typic
vaccin
antigen
display
scaffold
molecul
form
defin
nanostructur
nanoparticl
nanotub
nanosheet
vaccin
antigen
typic
conjug
scaffold
genet
fusion
either
ie
singl
polypeptid
construct
adaptor
molecul
eg
streptavidinbiotin
interact
coval
chemic
crosslink
approach
advantag
challeng
best
approach
may
vari
depend
target
immunogen
genet
fusion
alway
feasibl
mani
fusion
partner
disrupt
assembl
underli
multimer
scaffold
protein
hand
genet
fusion
system
allow
precis
control
antigen
orient
occup
ie
surfac
densiti
antigen
gener
simpl
product
pipelin
genet
fusion
system
recent
use
creat
selfassembl
vaccin
immunogen
influenza
viru
respiratori
syncyti
viru
rsv
epsteinbarr
viru
ebv
influenza
nanoparticl
studi
viral
hemagglutinin
ha
envelop
protein
truncat
ha
stem
protein
abl
trimer
three
fold
symmetr
axe
selfassembl
nanoparticl
base
bacteri
ferritin
protein
mani
type
viral
envelop
protein
exist
homotrim
surfac
natur
virion
exampl
virus
trimer
envelop
protein
includ
rsv
human
metapneumoviru
coronavirus
eg
middl
eastern
respiratori
syndrom
viru
ebola
virus
thu
suitabl
ferritin
platform
rigid
multival
display
trimer
antigen
open
opportun
creat
complex
nanoparticul
vaccin
immunogen
also
possibl
use
symmetr
axe
ferritin
encapsulin
anoth
bacteri
protein
recent
success
engin
nanoparticl
vaccin
platform
viral
capsid
first
wide
use
nanoparticl
scaffold
display
antigen
interest
rigid
multival
array
one
earliest
use
vlp
assembl
core
protein
hepat
b
viru
hbcag
abl
display
exogen
footandmous
diseas
viru
fmdv
epitop
nm
hbcag
particl
abl
elicit
fmdvspecif
immun
respons
anim
substanti
higher
magnitud
compar
respons
elicit
nonnanoparticul
scaffold
free
peptid
epitop
alon
sinc
structur
biolog
biochem
techniqu
continu
matur
viral
capsid
protein
util
display
variou
epitop
protein
antigen
one
advantag
use
viral
capsid
hbcag
bacteriophagederiv
capsid
protein
vlp
produc
highyield
bacteri
express
system
easili
scalabl
vaccin
manufactur
typic
extens
gene
insert
exogen
target
antigen
limit
platform
either
size
shape
orient
antigen
combin
factor
thu
often
difficult
display
larger
antigen
entir
viral
envelop
protein
exampl
hbcag
versatil
platform
present
rel
larg
protein
proper
nanoparticl
assembl
disrupt
nand
ctermini
antigen
interest
distant
one
anoth
problem
partial
resolv
introduc
enzymat
cleavag
site
near
hbcaginsert
site
therebi
releas
one
terminu
insert
relax
core
protein
scaffold
allow
particl
assembl
prokaryot
express
system
possibl
incorpor
unnatur
amino
acid
nanoscaffold
make
suitabl
chemic
conjug
multipl
vlp
system
use
technolog
conjug
exogen
antigen
surfac
particl
method
especi
power
antigen
interest
requir
specif
tertiari
quaternari
structur
disulfid
bond
format
glycosyl
posttransl
modif
elicit
desir
immun
respons
conjug
antigen
acceptor
scaffold
allow
separ
express
scaffold
antigen
heterolog
express
purif
system
effici
chemic
conjug
vari
differ
system
distribut
occup
orient
antigen
scaffold
surfac
difficult
control
factor
partli
manipul
conjug
condit
ie
concentr
antigen
scaffold
genet
design
restrict
number
reactiv
residu
scaffold
antigen
recent
altern
conjug
techniqu
describ
bacteriophag
capsid
system
adaptor
protein
call
dec
decor
protein
use
link
target
antigen
particl
scaffold
dec
protein
assembl
trimer
principl
attach
trimer
protein
influenza
ha
envelop
ebola
viru
glycoprotein
rsv
fusion
protein
coronaviru
spike
protein
anoth
recent
studi
report
use
streptococcu
pyogen
fibronectin
bind
proteinbas
spytagspycatch
system
predict
coval
linkag
antigen
one
earliest
wellestablish
system
made
use
chemic
conjug
biotin
hpv
vlp
scaffold
surfac
therebi
allow
tetramer
streptavidin
serv
bridg
display
biotinyl
protein
antigen
addit
virion
structur
protein
mani
group
protein
natur
form
higherord
multim
geometr
rigid
suitabl
vaccin
antigen
display
multival
nonvir
protein
chaperon
enzym
complex
requir
multimer
state
specif
biolog
function
ferritin
perhap
bestcharacter
exampl
nonvir
protein
nanoparticl
engin
multipl
applic
includ
semiconductor
vivo
contrast
agent
diagnost
biosensor
also
use
carrier
protein
deliv
therapeut
agent
vaccin
antigen
earli
attempt
primarili
focus
attach
simpl
peptid
epitop
surfac
selfassembl
ferritin
particl
use
tractabl
prokaryot
product
system
outlin
ferritin
platform
shown
robust
humor
immunogen
anim
model
seem
like
move
forward
toward
clinic
trial
anoth
success
exampl
categori
base
bacteri
enzym
lumazin
synthas
analog
ferritin
singl
subunit
protein
selfassembl
icosahedr
particl
ident
build
block
thu
potenti
use
multival
display
monomer
antigen
although
ferritin
lumazin
synthas
nanoparticl
rel
small
diamet
nm
compar
typic
virion
viral
capsid
recombin
antigendecor
nanoparticl
size
rang
shown
recapitul
bachmannzinkernagel
effect
furthermor
demonstr
certain
mutat
lumazin
synthas
lead
assembl
larger
nanoparticl
studi
ebv
vaccin
candid
receptorbind
domain
ebv
link
either
ferritin
anoth
slightli
larger
nm
diamet
scaffold
assembl
bacteri
encapsulin
protein
subunit
type
antigennanoparticl
elicit
similar
magnitud
humor
respons
ebv
antigen
suggest
nanoparticl
size
significantli
affect
immunogen
context
encapsulin
platform
also
engin
encapsid
protein
lumen
nanoparticl
attach
specif
signal
sequenc
encapsid
protein
accentu
potenti
creat
nanoparticul
vaccin
immunogen
deliv
encapsid
adjuv
molecul
costimulatori
molecul
tlr
agonist
proteinac
nanoparticl
made
mammalian
cell
simpli
introduc
secret
signal
sequenc
secret
subunit
protein
fuse
antigen
spontan
selfassembl
nanoparticl
milieu
er
lumen
purifi
nanoparticl
cultur
supernat
straightforward
chromatographi
techniqu
advantag
approach
fuse
antigen
interest
fold
properli
acquir
natur
pattern
posttransl
modif
glycosyl
known
critic
proper
fold
mani
viral
envelop
protein
mani
addit
class
nanoparticl
remain
explor
vaccin
antigen
display
scaffold
exampl
unexplor
area
disciplin
includ
bacteri
microcompart
complex
scaffold
vertebr
immun
system
compon
recogn
multival
antigen
latter
may
includ
complement
compon
igm
mannos
bind
protein
mbp
relat
highli
oligomer
lectin
vertebratederiv
scaffold
might
advantag
persist
fdc
immun
cell
specif
receptor
igm
mbp
next
gener
nanoparticl
could
includ
featur
condit
assemblydisassembl
higher
order
regul
coassembl
prototyp
system
condit
assembl
explor
engin
ferritin
redesign
monomermonom
interfac
carri
metalbind
site
smoothen
surfac
render
assembl
depend
presenc
metal
ion
present
exampl
use
proteinac
nanoparticl
accommod
multipl
insert
might
allow
display
heterooligomer
antigen
interest
possibl
type
display
could
achiev
use
scaffold
compris
one
type
build
block
platform
might
includ
twosubunit
insect
ferritin
threesubunit
hydrogenes
nanoparticl
altern
might
possibl
obtain
complex
split
design
break
singl
subunit
protein
two
smaller
part
sum
field
vaccin
design
util
synthet
proteinac
selfassembl
nanoparticl
platform
alreadi
well
past
infanc
aforement
candid
soon
enter
human
clinic
trial
like
new
class
immunogen
possess
superior
immunogen
provid
rapid
flexibl
scalabl
manufactur
subunit
vaccin
near
futur
de
novo
design
synthet
selfassembl
nanoparticl
modern
comput
approach
increasingli
pois
solv
challeng
structur
biolog
question
previous
impervi
experiment
investig
first
attempt
util
synthet
build
block
make
selfassembl
molecul
scaffold
display
exogen
antigen
start
simpl
structurestwo
helic
link
loopto
recreat
two
threeand
fivefold
symmetri
axe
canon
icosahedr
particl
protein
model
becom
increasingli
accur
reliabl
larger
complex
subunit
build
block
design
protein
build
block
design
silico
selfassembl
quaternari
complex
nanoparticl
comput
approach
might
offer
path
implement
function
condit
assemblydisassembl
may
offer
improv
immunogen
challeng
antigen
structur
plastic
env
protein
vlp
selfassembl
proteinac
nanoparticl
power
platform
present
antigen
humor
immun
system
platform
repres
geometr
rigid
repetit
array
antigen
contrast
solubl
monomer
protein
subunit
capabl
robustli
trigger
pampmedi
immun
stimul
b
cell
addit
highli
success
current
vlpbase
vaccin
hpv
mani
vlpnanoparticlebas
vaccin
candid
recent
enter
preclin
clinic
trial
potenti
applic
new
class
vaccin
platform
broad
seem
pois
serv
import
next
gener
vaccin
